Downloads
Abstract
Background: For advanced gastric cancer, there is no regimen approved as standard first - line therapy. In the attempt to improve the treatment outcome of advanced gastric cancer, modified - DCF (mDCF) has been widely applied. This study aimed to evaluate the efficacy and safety of the combination of modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) as the frist line chemotherapy in patients with advanced and recurrent gastric cancer who no longer curable.
Methods: This is a mixed study of retrospective and prospective cohorts, involving 32 patients diagnosed with advanced gastric cancer in K Hospital who underwent mDCF as first-line chemotherapy.
Results: The disease control rate was 87.5% (complete response, 9.4%; partial response, 59.4%; stable disease, 18.7%; progressive disease, 12.5%). The median progression - free survival (PFS) was 8,7 months. Grade 3 or 4 hematological toxicity occurred in seven patients (21.9 %) with leukopenia in 2 patients (6.2%) and neutropenia in 5 patients (15.6%), and no grade 3 or 4 of non - hematological toxicity developed.
Conclusions: mDCF as first - line chemotherapy is safe and effective, with a relatively improved response rate, and long PFS in patients with advanced and recurrent gastric cancers.
References
Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Nguyễn Bá Đức. Lịch sử nghiên cứu và tình hình bệnh ung thư, Dịch tễ học bệnh ung thư. Nhà xuất bản Y học, Hà Nội. 2008.
Wagner A.D., Syn N.L., Moehler M. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017.
Tomasello G., Liguigli W., Poli R. et al. Efficacy and tolerability of chemotherapy with modified dose - dense TCF regimen (TCF - dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial. Gastric Cancer. 2014;17(4):711-717.
Keskin S., Yıldız I., Sen F. et al. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). Clin Transl Oncol. 2013;15(5):403-408.
Salvon - Harman J.C. Shifting Proportions of Gastric Adenocarcinomas. Arch Surg. 1994;129(4):381.
Nagtegaal I.D., Odze R.D., Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76(2):182-188.
Vũ Văn Thế. Đánh giá kết quả hóa trị phác đồ Docetaxel - Cisplatin trong bệnh ung thư dạ dày giai đoạn muộn tại bệnh viện K, Đại học Y Hà Nội. 2015.
Gastric cancer, NCCN guidelines.
Shah M.A., Janjigian Y.Y., Stoller R. et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015;33(33):3874-3879.
Tô Như Hạnh. Đánh giá kết quả hóa trị liệu phác đồ EOX cho ung thư dạ dày giai đoạn muộn không còn khả năng phẫu thuật triệt căn. Đại học Y Hà Nội. 2012.
Nguyễn Văn Hiếu, Nguyễn Thị Hường. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị phẫu thuật ung thư dạ dày sớm tại bệnh viện K từ 2000 - 2006. Tạp Chí Ung Thư Học Việt Nam. 2008;176-181. .
Nguyễn Khánh Hà. Đánh giá kết quả điều trị ung thư dạ dày tái phát - di căn bằng phác đồ TCX, Đại học Y Hà Nội. 2009.
Pourghasemian M., Danandeh Mehr A., Molaei M. et al. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma. Asian Pac J Cancer Prev. 2020;21(8):2337-2341.
Yang D., Hendifar A., Lenz C. et al. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011;2(2):77-84.
Chau I., Norman A.R., Cunningham D. et al. Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer - Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data. J Clin Oncol. 2004; 22(12): 2395-2403.
| Published | 01-08-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.20 | |
| Keywords | Ung thư dạ dày, hóa chất bước 1, mDCF Advanced gastric cancer, first - line chemotherapy, mDCF |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital